Selecting ligand agonists and antagonists

Details Selecting ligand agonists and antagonists Selecting ligand agonists and antagonists

2005-08-30

2005-08-30

Saoud, Christine J. (Department: 1647)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069100, C435S069500, C435S069520, C435S071100, C435S069510, C435S243000, C435S325000, C536S023500, C536S023510, C536S023520, C530S399000

Reexamination Certificate

active

06936440

ABSTRACT:
We have discovered that growth hormones from ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described.

REFERENCES:
patent: 4857637 (1989-08-01), Hammonds et al.
patent: 4871835 (1989-10-01), Aviv et al.
patent: 5073540 (1991-12-01), Olsson
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5580723 (1996-12-01), Wells et al.
patent: 5681809 (1997-10-01), Kopchick et al.
patent: 6238915 (2001-05-01), Chihara
patent: 0 103 395 (1984-03-01), None
patent: 0 333 348 (1989-09-01), None
patent: 0 333 349 (1989-09-01), None
patent: 2 073 245 (1981-10-01), None
patent: WO 86/01229 (1986-02-01), None
patent: WO 88/07084 (1988-09-01), None
patent: WO 90/04788 (1990-05-01), None
patent: WO 90/05185 (1990-05-01), None
patent: WO 91/02754 (1991-03-01), None
patent: WO 91/05853 (1991-05-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/19736 (1992-11-01), None
patent: WO 93/00109 (1993-01-01), None
patent: WO 92/21029 (1995-11-01), None
Nicoll et al. Endocrine Rev. 7(2): 169-203, 1986.
Cunningham et al. Science 244: 1081-1085, 1989.
Ashkenazi, A., et al., “Comparative Study of in Vitro and in vivo Modulation of Lactogenic and Somatotrophic Receptors by Native Human Growth Hormone and Its Modified Analog Prepared by Recombinant Deoxyribonucleic Acid Technology,”Endocrinology121:414-419 (1987).
Aston, R., et al., “Antigenic Structure of Bovine Growth Hormone: Location of a Growth Enhancing Region,”Molecular Immunology,28:41-50 (1991).
Bamborough, P., et al., “Predictive Modelling of the 3-D Structure of Interleukin-13,”Protein Engineering7:1077-1082 (1994).
Bamborough, P., et al., “A Computer Model of the Interleukin-4/Receptor Complex,”Proteins, Structure, Function&Genetics17:11-19 (1993).
Bass, S., et al., “A systematic mutational analysis of hormone-binding determinants in the human growth hormone receptor,”Proc. Natl. Acad. Sci.88:4498-4502 (1991).
Binder, L., et al., “Site-Directed Mutations of Human Growth Hormone that Selectively Modify Its Lactogenic Activity and Binding Properties,”Molecular Endocrinology4:1060-1068 (1990).
Chen, W., et al., “Functional Antagonism between Endogenous Mouse Growth Hormone (GH) and a GH Analog Results in Dwarf Transgenic Mice,”Endocrinology129:1402-1408 (1991).
Chen, W., et al., “Glycine 119 of Bovine Growth Hormone is Critical for Growth-Promoting Activity,”Molecular Endocrinology5:1845-1852 (1991).
Chen, W., et al., “Mutations in the Third α-Helix of Bovine Growth Hormone Dramatically Affect Its Interacellular Distribution in Vitro and Growth Enhancement in Transgenic Mice,”J. Biol. Chem.266:2252-2258 (1991).
Chen, W., et al., “Expression of a mutated bovine growth hormone gene suppresses growth of transgenic mice,”Proc. Natl. Acad. Sci.87:5061-5065 (1990).
Chiba, S., et al., “Identification and Cellular Distribution of Distinct Proteins Forming Human GM-CSF Receptor,”Cell Regulation1:327-335 (1990).
Cosman, D., et al., “A new cytokine receptor superfamily,”TIBS15:265-270 (1990).
Cunningham, B., et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,”Science244:1081-1085 (1989).
Cunningham, B., et al., “Engineering Human Prolactin to Bind to the Human Growth Hormone Receptor,”Science247:1461-1465 (1990).
Cunningham, B., et al., “Dimerization of the Extracellular Domain of the Human Growth Hormone Receptor by a Single Hormone Molecule,”Science254:821-8215 (1991).
Davis, S., et al., “LIFRβ and gp 130 as Heterodi- merizing Signal Transducers of the Tripartite CNTF Receptor,”Science260:1805-1808 (1993).
Demchuk, E., et al., “Receptor Binding Properties of Four-Helix-Bundle Growth Factors Deduced From Electrostatic Analysis,”Protein Science3:920-935 (1994).
Devos, R., et al., “Molecular Basis of a High Affinity Murine Interleukin-5 Receptor,”The EMBO Journal10:2133-2137 (1991).
de Vos, A., et al., “Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex”,Science255:306-312 (1992).
Diederichs, K., et al., “Novel Fold and Putative Receptor Binding Site of Granulocyte-Macrophage Colony-Stimulating Factor,”Science254:1779-1782 (1991).
Fuh, G., et al., “Mechanism-Based Design of Prolactin Receptor Antagonists,”J. Biol. Chem.268:5376-5381 (1993).
Fuh, G., et al., “Rational Design of Potent Antagonists to the Human Growth Hormone Receptor,”Science256:1677-1680 (1992).
Gooley, P., et al., Location of an α-Helix in Fragment 96-133 from Bovine Somatotropin by1H NMR Spectroscopy,Biochemistry27:4032-4040 (1988).
Gunther, N., et al., “The Secreted Form of the Epidermal Growth Factory Receptor,”J. Biol. Chem.265:22082-22085 (1990).
Haniu, M., et al., “Recombinant Human Erythropoietin (rHuEPO): Cross-linking With Disuccinimidyl Esters and Identification of the Interfacing Domains in EPO,”Protein Science2:1441-1452 (1993).
Heldin, C., et al., “Dimerization of B-type Platelet-derived Growth Factor Receptors Occurs after Ligand Binding and Is Closely Associated with Receptor Kinase Activation,”J. Biol. Chem.264:8905-8912 (1989).
Kadar, T., et al., “Decrease in Prolactin Receptor Affinity in the Rat Mammary Tumor Model After Treatment with Analogs of Samatostatin and LH-RH,”Chemical Abstracts110 (1989).
Kondo, M., et al., “Sharing of the Interleukin-2 (IL-2) Receptor γ Chain Between Receptors for IL-2 and IL-4,”Science262:1874-1877 (1993).
Kostyo, J., “The Multivalent Nature of Growth Hormone,”Human Growth Hormone33:449-453 (1986).
Lambert, G., et al., “Crystallization and Preliminary X-ray Diffraction Studies of a Complex between Interleukin-2 and a Soluble Form of the p55 Component of the High Affinity Interleukin-2 Receptor,”J. Biol. Chem. 264:12730-12736; (1989).
Leroy-Martin, B., et al., “Modulation of Prolactin Receptors (PRL-R) by Lactogenic and Steroid Hormones in Human Breast Cancer Cells in Long-Term Tissue Culture,”Chemical Abstracts111:110 (1989).
Lokker, N., et al., “Structure-Activity Relationship Study of Human Interleukin-3,”J. Biol. Chem.266:10624-10631 (1991).
Lowman, H., et al., “Mutational Analysis and Protein Engineering of Receptor-binding Determinants in Human Placental Lactogen,”J. Biol. Chem.266:10982-10988 (1991).
Miyajima, A., et al., “Common Subunits of Cytokine Receptors and the Functional Redundancy of Cytokines,”TIBS17 (1992).
Murakami, M., et al., “IL-6-Induced Homodimerization of gph 130 and Associated Activation of a Tyrosine Kinase,”Science260:1808-1810 (1993).
Nicola, N., et al., “Subunit Promiscuity Among Hemopoietic Growth Factor Receptors,”Cell67:1-4 (1991).
Noguchi, M., et al., “Interleukin-2 Receptor γ Chain: A Functional Component of the Interleukin-7 Receptor,”Science262:1877-1880 (1993).
Nowak, R., et al., “Bubble Boy Paradox Resolved,”Science26

Affiliated with

Also associated with

Rating

Selecting ligand agonists and antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selecting ligand agonists and antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selecting ligand agonists and antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3479155